The scientific journal Nature highlighted the platform's versatility and speed, which noted that many mRNA companies now utilize variations of the Mandl team's technology. Despite the significance of these advancements, GSK argues that Moderna has never acknowledged its reliance on GSK's patented platform. Instead, Moderna has focused on promoting the speed and efficiency of its mRNA vaccines, such as Spikevax, which have been modified to address different strains of the SARS-CoV-2 virus. GSK now seeks to recover royalties for what it claims are unauthorized sales of vaccines that infringe on its intellectual property. The lawsuit emphasizes that Moderna has benefited financially from GSK's patented technology without securing the necessary licenses. GSK aims to secure compensation for Moderna's use of its innovative mRNA vaccine platform.